My research is focused on identifying mechanisms and treatment for patients with chronic kidney diseases. A major effort of my laboratory is in the diagnosis and treatment of diabetic nephropathy, the most common cause of chronic kidney disease. The laboratory conducts studies on treatment with novel drugs and drug combinations designed to slow or stop progression of established chronic kidney disease. In addition, my laboratory is interested in identifying risk factors for progression of kidney disease which may lead to novel therapies to treat and ultimately prevent chronic kidney disease.
RESEARCH INTERESTS
Hypertension in Chronic Kidney Disease
Hemodialysis Techniques and Management
Diabetic Nephropathy Pathogenesis and Treatment
Cardiovascular Morbidity and Mortality in Chronic Kidney Disease
RECENT PUBLICATIONS
Henrich WL, Clark RL, Kelly JP et al., "Non-contrast-enhanced computerized tomography and analgesic-related kidney disease: report of the national analgesic nephropathy study" J Am Soc Nephrol, 17:1472-1480, 2006
Keane WF, Zhang Z, Lyle PA, Cooper ME, de Zeeuw D, Grunfeld JP, Lash JP, McGill JB, Mitch WE, Remuzzi G, Shahinfar S, Snapinn SM, Toto R, Brenner BM; RENAAL Study Investigators., "Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study." Clinical Journal American Society of Nephrology, 1:761-767, July 2006
Toto, RD, "Treatment of hypertension in chronic kidney disease" Semin Nephrol, 25:435-439, 2005
Tuttle KR, Bakris GL, Toto RD et al., "The effect of ruboxistaurin on nephropathy in type 2 diabetes" Diabetes Care, 28:2686-2690, 2005
Toto RD, Pichette V, Navarro J et al., "Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration" Am J Nephrol, 24:453-460, 2004
Baber U. ,Toto R.D., de Lemos J.A, "Statins and cardiovascular risk reduction in patients with chronic kidney disease and end-stage renal failure" Am Heart J., 153(4):471-477, April 2007
SIGNIFICANT PUBLICATIONS
Mohanram A, Zhang Z, Shahinfar S et al., "Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy" Kidney Int, 66:1131-1138, 2004
Keane WF, Brenner BM, de Zeeuw D, Grunfeld JP, McGill J, Mitch WE, Bibeiro AB, Shahinfar S, Simpson RL, Snapinn SM, Toto R., "The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL Study" Kidney Int, 63:1499-1507, 2003
Chertow GM, Raggi P, McCarthy JT et al., "The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients" Am J Nephrol, 23:307-314, 2003
Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G, Schwab SJ, Teehan BP, Toto R., "Effect of dialysis dose and membrane flux in maintenance hemodialysis" N Engl J Med, 347:2010-2019, 2002
Point and right click (click and hold for Mac users) your mouse onand select "Save this link (or target) as..." option to save the file to your local computer.
and select "Save this link (or target) as..." option to save the file to your local computer.